BeOne Medicines's ROE % for the quarter that ended in Mar. 2026 was 19.94%. BeOne Medicines's PB Ratio for the quarter that ended in Mar. 2026 was 6.93.
BeOne Medicines's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 2.88%.
BeOne Medicines ROE % Adjusted to Book Value Related Terms
BeOne Medicines ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines ROE % Adjusted to Book Value Chart
ONC vs RVMD, RPRX, BNTX: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, BeOne Medicines's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 2.88% mean?
BeOne Medicines (ONC) has a ROE % Adjusted to Book Value of 2.88% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' ROE % Adjusted to Book Value too high?
BeOne Medicines' current ROE % Adjusted to Book Value is 2.88%. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' ROE % Adjusted to Book Value compare to RVMD and RPRX?
BeOne Medicines' ROE % Adjusted to Book Value of 2.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current ROE % Adjusted to Book Value is 2.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $280.00 — trading 23.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 2.88%. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BeOne Medicines (ONC), the current ROE % Adjusted to Book Value is 2.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
ROE % Adjusted to Book Value: 2.88%
GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for ONC
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
